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Abstract
Background and Purpose: Fatty acid binding protein 4 (FABP4) has been shown to play an important role in macrophage
cholesterol trafficking and associated inflammation. To further elucidate the role of FABP4 in atherogenesis in humans, we
examined the regulation of FABP4 in carotid atherosclerosis and ischemic stroke.
Methods: We examined plasma FABP4 levels in asymptomatic (n=28) and symptomatic (n=31) patients with carotid
atherosclerosis, as well as in 202 subjects with acute ischemic stroke. In a subgroup of patients we also analysed the
expression of FABP4 within the atherosclerotic lesion. In addition, we investigated the ability of different stimuli with
relevance to atherosclerosis to regulate FABP4 expression in monocytes/macrophages.
Results: FABP4 levels were higher in patients with carotid atherosclerosis, both systemically and within the atherosclerotic
lesion, with particular high mRNA levels in carotid plaques from patients with the most recent symptoms. Immunostaining
of carotid plaques localized FABP4 to macrophages, while activated platelets and oxidized LDL were potent stimuli for
FABP4 expression in monocytes/macrophages in vitro. When measured at the time of acute ischemic stroke, high plasma
levels of FABP4 were significantly associated with total and cardiovascular mortality during follow-up, although we did not
find that addition of FABP4 to the fully adjusted multivariate model had an effect on the prognostic discrimination for all-
cause mortality as assessed by c-statistics.
Conclusions: FABP4 is linked to atherogenesis, plaque instability and adverse outcome in patients with carotid
atherosclerosis and acute ischemic stroke.
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Introduction
Atherosclerosis is a chronic disease characterized by two
fundamental hallmarks: lipid accumulation and inflammation.
[1] The interaction between these two processes defines the
principal pathogenesis of atherosclerosis, and distinguishes it from
other chronic inflammatory disorders. Carotid atherosclerosis may
result in cerebral embolization and symptoms of cerebral ischemia
leading to transient ischemic attack (TIA) or stroke. While the
interaction between inflammation and lipids leads to progression
of carotid plaques with the development of symptomatic lesions;
[1,2] the molecular mechanisms for these events are not fully
understood.
Fatty acid binding proteins (FABPs) are cytosolic proteins that
function as lipid chaperones and are involved in lipid signalling
cascades. [3] Amongst the FABPs, FABP4 (aP2) is of special
interest in atherogenesis. While originally described as an adipose
tissue protein, [4,5] recent work has shown a pivotal role for
FABP4 in macrophages in relation to cholesterol trafficking and
inflammation. [6,7] In line with this, total or macrophage-specific
FABP4 (aP2)-deficiency has been shown to protect against
atherosclerosis in apolipoprotein E-deficient (ApoE
-/-) mice, [8]
and FABP4 has been suggested as a potential drug target in
diseases like diabetes and atherosclerosis. [6] Two very recent
studies have shown enhanced FABP4 expression within human
carotid atherosclerotic lesions in association with poor prognosis,
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28785[9,10] but the role and regulation of FABP4 in clinical
atherosclerosis is still unclear.
To further elucidate the role of FABP4 in atherogenesis in
humans, we examined the regulation of FABP4 in atherosclerosis
and ischemic stroke in three different ways: (i) In a cross-sectional
study of patients with symptomatic and asymptomatic carotid
plaques we analyzed FABP4 levels in plasma and plaque samples.
(ii) In an in vitro study, we examined the regulation of FABP4 in
monocytes/macrophages. (iii) In a separate sub-study, we
examined the association between plasma levels of FABP4 in
acute ischemic stroke and mortality during long-term follow-up.
Materials and Methods
Ethics
The study was approved by the Regional Committee of Medical
and Health Research Ethics (REK) in Eastern Norway and signed
informed consent was obtained from all individuals.
Patients and controls
Cross-sectional study. Patients with high-grade internal
carotid stenoses ($70%) treated with carotid endarterectomy or
carotid angioplasty with stenting were consecutively recruited to
the study. Patients were classified as asymptomatic and
symptomatic according to the absence or presence of clinical
symptoms such as stroke, TIA or amaurosis fugax ipsilateral to the
stenotic internal carotid artery within the past 6 months. Carotid
stenoses were diagnosed and classified by precerebral color Duplex
ultrasound and CT angiography according to consensus criteria.
[11] Asymptomatic carotid stenoses were detected during clinical
examinations of patients with coronary artery disease (CAD),
peripheral artery disease or stroke/TIA more than six months ago.
The plaques were also divided into two groups (i.e., echolucent or
echogenic/heterogeneous) depending on plaque echogenicity on
ultrasound examination. [11] Plasma samples were analyzed from
31 symptomatic and 28 asymptomatic patients, whereas plaque
mRNA expression was analyzed in 42 symptomatic and 12
asymptomatic. All patients were recruited from the same cohort,
and we attempted to collect plasma and plaques from all patients,
but in some cases this was not possible. For comparisons, blood
samples were also collected from 18 sex- and age-matched healthy
individuals recruited from the same area of Norway as the patients
(eastern part). Although asymptomatic atherosclerosis can not be
totally excluded, all the controls were evaluated as healthy based
on clinical examination, disease history and analyses of C-reactive
protein (CRP) and lipid parameters (Table 1).
Patients with acute stroke – longitudinal follow-up
study. Between August 2003 and October 2004, 790 patients
with acute ischemic stroke admitted to the Department of
Neurology, Odense University Hospital, Odense, Denmark were
consecutively screened for inclusion into the study. [12] Patients
with overt ischemic heart disease (n=177) (i.e., any prior
myocardial infarction, stable or unstable angina pectoris,
pathological Q-waves on the baseline electrocardiogram,
previous coronary angioplasty or coronary bypass surgery),
patients with current atrial fibrillation (n=132), patients with
onset of stroke symptoms .7 days before admission (n=75) were
not included. In addition, 70 patients were excluded because of
Table 1. Baseline variables in patients according to symptomatic
# and asymptomatic carotid plaques (n=59) and healthy controls
(n=18).
Symptomatic
plaques (n=31)
Asymptomatic
plaques (n=28) p Controls (n = 18)
Age, year 66.8 (8.8, range 50–83) 65.3 (9.4, range 44–81) .533 59 (6, range 47–70)
Male sex* 21 (67.7) 19 (67.9) .992 17 (85)
Current smoking
* 20 (64.5) 16 (57.1) .562 2 (10)
Degree of stenoses, % 80 (60–95) 80 (60–95) .724 n.d.
Echolucent carotid plaque* 12 (38.7) 8(28.6) .411 n.d.
Ipsilateral ischemia on cerebral MRI* (n=47) 23 (74.2) 18 (64.3) .887 n.d.
Body mass index, kg/m
2 25 (20–36) 27 (19–35) .164 n.d.
Systolic blood pressure,mmHg 152 (110–200) 149 (111–176) .323 n.d.
Diastolic blood pressure, mmHg 79.5 (32–101) 77.5 (49–99) .222 n.d.
Statin treatment
* 26 (83.9) 25 (89.3) .544 0
Aspirin treatment
* 27 (87.1) 23 (82.1) .587 0
FABP4 ng/ml 32.3 (14.4 ) (median
28.3, range 18.5–78.4)
29.1 (7.5) (median
29.2, range 14.1–43.3)
.294 19.0 (4.3) (median 18.5,
range 7.2–25.1)
CRP, mg/l 4.1 (1.0–39.0) 5 (1.0–28.0) .724 1.01 (0.3)
Total leukocyte count, 10
9/l 8.1 (2.1) 7.1 (1.6) .044 n.d.
Cholesterol, mmol/l 4.5 (0.9) 4.2 (0.91) .154 4.3 (0.6)
HDL cholesterol, mmol/l (n=88) 1.4 (0.5) 1.3 (0.4) .584 1.4 (0.3)
LDL (n=78) 2.8 (0.82) 2,5 (0.75) .189 2.6 (0.6)
HbA1c, % 6.0 (0.9) 6.0 (1.0) .839 n.d.
Platelet count, 10
9/l 257 (73.4) 266 (47.5) .593 n.d.
P-value: Symptomatic patients vs asymptomatic.
#Clinical symptoms include stroke, TIA or amaurosis fugax ipsilateral to the stenotic internal carotid artery within the last 6 months. Values are mean (SD) in normally
distributed data, median (range) in skewed data or *numbers (percentages).
doi:10.1371/journal.pone.0028785.t001
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in 10 patients the stroke diagnosis was revised after re-evaluation
and 15 patients were excluded of other reasons. Finally, 47
patients were unwilling to participate, rendering 244 patients
eligible for inclusion in the study, of which plasma samples were
available from 202 patients (Table 2). Clinical evaluations were
performed by a senior neurologist that was blinded to the
biomarkers, and the presence of intracerebral or subarachnoid
hemorrhage was ruled out by computed tomography at the time of
admission. Patient demographics along with past and present
clinical history including medication were obtained by
interviewing the patient and from medical records. Relatives
provided this information if the patient was unable to take part in
the interview. Renal failure was defined as plasma creatinine
.120 mmol/L. Heart failure (HF) was considered present if the
patients had a left ventricular ejection fraction ,50% and/or if a
patient had previously been given the diagnosis of HF by a
physician. Stroke severity was assessed using the Scandinavian
Stroke Scale (SSS). [13] Patients with concomitant inflammatory
disease (e.g., infection or autoimmune disorders), malignancies or
liver disease were excluded from follow-up.
Blood Sampling Protocol
Peripheral venous blood was drawn into pyrogen-free EDTA
tubes which were immediately immersed in melting ice and
centrifuged at 2500 g for 25 minutes within 20 minutes to obtain
platelet-poor plasma. All samples were stored at –80uC; samples
were thawed only once before analyses.
Carotid Endarterectomy Specimens
Atherosclerotic carotid plaques were retrieved from patients
during carotid endarterectomy. Plaques that were used for RNA
extraction were rapidly frozen in liquid nitrogen. Plaques that
were used for histological analyses were put in 4% phosphate
buffered-formalin for 48 hours and then embedded in paraffin.
Real-Time Quantitative Reverse Transcription Polymerase
Chain Reaction
Total RNA was isolated from frozen THP-1 monocytes and
carotid tissue with the use of RNeasy spin columns (QIAGEN,
Hilden, Germany) and stored at –80uC until further analysis.
cDNA was synthesized using high-capacity cDNA archive kit
(Applied Biosystems, Foster City, CA). Primers for FABP4
(forward primer [FP]: 59-TTGACGAAGTCACTGCAGATGA-
39 and reverse primer [RP]: 59-CAGGACACCCCCATC-
TAAGGT-39), CD68 (FP 59-ATCCCCACCTGCTTCTCTCA-
39 and RP 59-GAGGTCCTGCATGAATCCAAA-39) and adi-
pose differentiation-related protein (ADFP) (FP 59-GAATCAGC-
CATCAACTCAGATTGT-39 and RP 59-AGTAGTCGTCA-
CAGCATCTTTTGC-39) were designed with the use of Primer
Express software version 3.0 (Applied Biosystems). Quantification
of mRNA was performed using the ABI Prism 7500 (Applied
Biosystems). SYBR Green assay was performed with the Power
SYBR Green Master Mix (Applied Biosystems). Gene expression
of the reference gene b-actin was used for normalization.
Immunohistochemistry
Sections (5 mm) of paraffin embedded atherosclerotic plaques
were treated with 0.5% H202, followed by high-temperature
unmasking in citrate-buffer (pH 6), blocked with 0.5% bovine
serum albumin (BSA) and then incubated with primary antibody
(rabbit anti-human FABP4; Abcam, Cambridge, UK) for one hour
at room temperature. After washing, the slides were incubated for
30 minutes with peroxidase-conjugated secondary antibodies
(Impress-Vector, Vector laboratories, Burlingame, CA), rinsed
and developed with chromogen for immunoperoxidase staining
(DAB Plus, Vector laboratories) for 7 minutes. The sections were
counterstained with Hematoxylin. Omission of the primary
antibody served as a negative control.
Immunfluorescence
Paraffin-embedded sections (5 mm) of atherosclerotic carotid
plaques were exposed to high-temperature unmasking (citrate-
buffer, pH 6), blocked in 0.5% BSA and incubated over night at
4uC with rabbit anti-human FABP4 (Abcam) and mouse anti-
human CD68 (Dako, Glostrup, Denmark). The sections were
counterstained with Alexa Fluor 488-conjugated goat anti-rabbit
IgG and Alexa Fluor 568-conjugated donkey anti-mouse IgG
(both from Invitrogen), respectively. Nuclei were stained with
diamidino-2-phenylindole (DAPI) (Slow Fade Gold antifade
reagent, Invitrogen). Fluorescent images were obtained on a
Nikon Eclipse E400 microscope with the 406objective.
Cell Culture Experiments
The human monocytic cell line THP-1 (American Type Culture
Collection, Rockville, MD) was cultured for 4 days in RPMI 1640
(PAA laboratories, Pasching, Austria), supplemented with 10%
fetal bovine serum (Gibco, Grand Island, NY), with and without
recombinant human tumor necrosis factor a (rhTNFa, 5 ng/ml;
R&D Systems, Minneapolis, MN), before further incubation with
or without lipopolysaccharide (LPS) from E. coli 026:B6 (5 ng/ml;
Sigma, St Louis, MO), a toll-like receptor (TLR)2 agonist
Table 2. Baseline characteristics of study patients.
Variable
Age, year 69613
Men 107 (53%)
History
Previous ischemic stroke 42 (21%)
Hypertension 111 (55%)
Diabetes Mellitus 24 (12%)
Lacunar infarction 97 (48%)
Total anterior circulation infarction 10 (5%)
Partial anterior circulation infarction 63 (31%)
Posterior circulation infarction 28 (14%)
Smoking 103 (51%)
Prior heart and/or renal failure 26 (13%)
Physical examination
Pulse 78615
Systolic blood pressure, mm Hg 175615
Diastolic blood pressure, mm Hg 93617
Scandinavian Stroke Scale score 47 (36–53)
Laboratory findings
Troponin T .0.03 g/L 14 (7%)
Hemoglobin, g/dL 8.5861.06
Creatinine, mg/dL 91 (80–103)
C-reactive protein, mg/L 5 (5–14)
Proportions are given as no. and (%). Continuous variables are given as mean 6
standard deviation or median and interquartile range depending on
distribution.
doi:10.1371/journal.pone.0028785.t002
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rh-interleukin (IL)-1b (1 ng/ml, R&D Systems) and platelet
releasate from un-stimulated and thrombin-activated platelets.
Platelet releasate was prepared as previously described. [14] After
24 hours, cell-free supernatants were collected and stored at –
80uC. In a separate experiment, THP-1 cells were differentiated
into macrophages by incubation for 24 hours with phorbol
myristate acetate (PMA, 100 nM; Sigma). At different time points,
cells were harvested in lysisbuffer and stored at –80uC until RNA
isolation. Some PMA-differentiated macrophages were further
stimulated with oxidized LDL (oxLDL, 20 mg/ml, prepared as
previously described), [15] with and without co-incubation with
TNFa (5 ng/ml) for 18 hours before harvesting.
Enzyme Immunoassay
FABP4 levels in plasma and cell supernatants were measured by
enzyme immunoassay (EIA) (BioVendor, Modrice, Czech Repub-
lic). Plasma levels of b-thromboglobulin (b-TG) were measured by
EIA from Diagnostica Stago (Asnie `res, France). CRP levels were
determined by a high-sensitivity particle enhanced immunoturbi-
dimetric assay on a Modular platform (Roche Diagnostic, Basel,
Switzerland). The intra- and inter-assay coefficient of variation
were ,10% for all assays.
Statistical Analyses
For comparisons of two groups of individuals, the Mann-
Whitney U test was used. When more than two groups were
compared, the Kruskal-Wallis test was used. If a significant
difference was found, the Mann-Whitney U test was used to
determine the differences between each pair of groups. In the in
vitro experiments, the Student’s t test and One-way ANOVA were
used as appropriate. Correlations were assessed by Pearson x2.
Receiver-operating characteristic (ROC) curves were established
for FABP4 as a predictor of death. Kaplan-Meier analysis with
log-rank test was performed to compare mortality rate in tertiles of
FABP4 (comparisons pooled over strata). The plasma FABP4
levels were highly skewed and we anticipated a non-linear
relationship with all-cause mortality. A restricted cubic spline
analysis with five knots was also undertaken to assess linearity of
risk. We chose tertiles as two groups (i.e. median) could fail to
detect a non-linear association between plasma FABP4 levels and
all-cause mortality, while we wanted to avoid too many small
groups. Based on the Kaplan Meier curves, the association seems
to be particularly strong in the third tertile. We therefore chose this
cut-off for subsequent analysis. The Cox proportional hazards
model was applied to assess the effect of FABP4 on survival at
follow-up. In the multivariate analyses, we included parameters
that were imbalanced between patients that survived and those
who died (p,0.1) including age, presence of HF, SSS score,
troponin T (TnT) levels .0.03 mg/L, MAP, stroke localization as
well as fasting blood glucose, and mean arterial pressure (MAP) as
an established risk factor for stroke. All continuous variables are
expressed per SD change in the regression analysis. When testing
the impact of the interaction term FABP4*SSS score, the following
variables were entered forced in the first block: age, presence of
HF, troponin T (TnT) levels .0.03 mg/L, fasting blood glucose,
MAP and stroke localization, while SSS score, FABP4 and the
interaction term SSS score*FABP4 were entered stepwise in the
next block. Harrel’s C-statistic was calculated for all-cause and
cardiovascular (CV) mortality using the full model with and
without admission levels of FABP4, and the difference between the
C-statistics was estimated. To correct for over-optimism associated
with validating a model in the same material from which it is
developed, we implemented a jack-knife cross-validation ap-
proach, where predictions for each observation were obtained
from models developed on the remaining observations. These
cross-validated probabilities were used to calculate jack-knife C-
statistics. In all tests, a p-value ,0.05 was considered statistically
significant.
Results
Increased plasma levels of FABP4 in patients with carotid
atherosclerotic plaques
Baseline characteristics of the study population (cross-sectional
study) where plasma levels of FABP4 were analyzed are shown in
Table 1. The study population included 40 men and 19 women,
median age 67 years (range 44–83 years). As depicted in Figure 1,
these 59 patients with carotid atherosclerosis had increased plasma
levels of FABP4 when compared with sex- and age-matched
healthy controls (n=18), but with no differences between patients
with asymptomatic (n=28) and symptomatic (n=31) carotid
lesion (p=0.29). The controls were comparable to the patients in
relation to sex and age, but the percentage of smokers was lower in
the control group. However, we found no correlation between
FABP4 and smoking habits, and it is therefore unlikely that the
enhanced levels of FABP4 in the patient group merely reflect an
increased percentage of smokers in these individuals. Within the
patient group as a whole, there was no relationship between
plasma levels of FABP4 and plaque echogenicity, and FABP4
levels in patients with the most recent symptoms (,1 month) were
not different from FABP4 levels in the other symptomatic patients
(data not shown).
We found no significant correlations between plasma levels of
FABP4 and lipid parameters in peripheral blood (triglycerides
[R
2=0.0071], total cholesterol [R
2=0.0125], LDL cholesterol
[R
2=0.0069] and HDL cholesterol [R
2=0.065]; p.0.1 for all
comparisons). Moreover, there were no significant correlations
between plasma levels of FABP4 and platelet counts (R
2=0.0036),
plasma levels of b-TG as a soluble marker of platelet activation
(R
2=0.0017) or CRP (R
2 = 0.048).
Figure 1. Increased plasma levels of FABP4 in patients with
carotid atherosclerotic plaques. Plasma levels of FABP4 were
measured by enzyme immunoassay in patients with asymptomatic
(n=28) and symptomatic (n=31) carotid plaques and healthy controls
(n=18). Data are mean6SEM. **p,0.001 compared to controls.
doi:10.1371/journal.pone.0028785.g001
FABP4 in Stroke
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atherosclerotic plaques from patients with recent
symptoms
We next examined mRNA levels of FABP4 in samples obtained
from asymptomatic (n=12) and symptomatic (n=42) carotid
lesions using real-time quantitative RT-PCR. The patients with
symptomatic lesion were further divided into two groups according
to their latest clinical symptoms (i.e., symptoms within the last 1
month [n=25] and symptoms within the last 1 to 6 months
[n=17]). As can be seen in Figure 2, levels of FABP4 mRNA were
significantly raised in plaques from patients with the most recent
symptoms (,1 month) as compared with the other patients with
symptomatic carotid plaques (1–6 months) and those with
asymptomatic lesions.
FABP4 is co-localized to macrophages within carotid
atherosclerotic plaques
We next examined the localization of FABP4 within plaques
that were obtained from 2 patients with symptomatic carotid
lesions (symptoms within the last month). Immunohistochemistry
showed strong FABP4 immunostaining within areas rich in
macrophages (Figure 3A), and the co-localization with macro-
phages was further supported by co-staining the plaques for both
FABP4 and the macrophage marker CD68 (Figure 3B). To further
examine the relationship between FABP4 and macrophages within
the atherosclerotic lesion, we estimated the degree of macrophage
infiltration by measurements of mRNA levels of the macrophage
maker CD68 by real-time RT-PCR. Interestingly, mRNA levels of
FABP4 were significantly correlated with mRNA levels of CD68
(R
2=0.264, P,0.001) (Figure 3C). Moreover, mRNA levels of
FABP4 were also significantly correlated with mRNA levels of the
lipid droplet marker ADFP (R
2=0.541, P,0.001) within the
atherosclerotic lesions (Figure 3C).
Oxidized LDL and platelets enhance FABP4 levels in THP-
1 monocytes/macrophages
As FABP4 was primarily expressed in macrophages within the
atherosclerotic lesion, we examined the ability of several stimuli
with relevance to atherosclerosis to modify FABP4 expression in
THP-1 monocytes/macrophages. Macrophage differentiation
(Figure 4A-left) and oxLDL (20 mg/ml) (Figure 4A-right)
markedly enhanced FABP4 mRNA expression in THP-1
macrophages. Inflammation could modulate FABP4 expression,
but the addition of rhTNFa (5 ng/ml) to oxLDL stimulated
THP-1 cells, carried out to mimic the inflammatory microen-
vironment within an atherosclerotic lesion, [16] did not
influence the expression of FABP4 in these cells (Figure 4A-
right). Thus, oxLDL induced FABP4 expression irrespective of
co-incubation with TNFa. Moreover, releasate from both un-
stimulated and in particular releasate from thrombin-activated
platelets markedly enhanced the release of FABP4 protein in
THP-1 monocytes that had been pre-incubated with rhTNFa
(5 ng/ml) for 96 hours (Figure 4B). Although platelet releasate
induced a release of FABP4 from THP-1 cells that had not been
pre-incubated with TNFa, the increase was rather modest and
with no difference between releasate from un-stimulated (1.6 +/
2 0.05 -fold increase) and thrombin-activated (1.5 +/2 0.06 -
fold increase) platelets. Thus, while the oxLDL-induced release
of FABP4 in THP-1 monocytes seems to be independent of
TNFa, the platelet-mediated release of this protein seems, at
least partly, to depend on TNFa pre-incubation. In contrast to
the effect of platelets, we found no effect of IL-1b,T L R 2a n d
TLR4 activation and the b-adrenergic receptor agonist
isoproterenol on FABP4 release from THP-1 cells that had
been pre-incubated with rhTNFa (5 ng/ml) for 96 hours
(Figure 4B).
High plasma levels of FABP4 are associated with long-
term mortality in patients with acute stroke
To further examine the relation of FABP4 to stroke, we
examined determinants of FABP4 and the ability of baseline
levels of FABP4 in plasma to predict long-term prognosis in 202
patients with acute ischemic stroke. Baseline characteristics of the
study population are described in Table 2. In a multivariable
stepwise linear regression model, the following were found to be
independent predictors of FABP4 concentrations (1SD change):
age (B=0.02, SE=0.01; p,0.001), gender (B=0.84, SE=0.13;
p,0.001), log serum creatinine (B=0.32, SE=0.07, p,0.001),
HDL cholesterol (B=20.48, SE=0.13, p,0.001) and SSS
(B=20.02, SE=0.01, p=0.002). At follow-up (median 4.4
years) 60 patients (29%) had died, 36 due to cardiovascular (CV)
reasons. ROC analysis indicated that the level of FABP4 at
admission had reasonable accuracy for the prediction of all-cause
(AUC=0.68; P ,0.001; Figure 5A) and CV (AUC=0.63;
P=0.012; Figure 5A) mortality at follow-up. Furthermore,
Kaplan–Meier analyses using tertiles of FABP4 revealed a
particularly high mortality rate in patients in the highest tertile
(i.e., FABP4 . 48 ng/mL) (Figure 5B), with an unadjusted
hazard ratio (HR) of 2.64 (95% CI=1.5924.38; P ,0.001) for
all-cause mortality and an unadjusted HR of 3.24 (1.67–6.29;
P=0.001) for CV mortality. Figure 5C shows the adjusted
restricted cubic spline analysis of FABP4 and all-cause mortality
indicating that the association with risk is non-linear. When
analyzed as a continuous variable, the unadjusted HR and 95%
CI for a 1 SD change in FABP4 was 1.61 (1.23–2.11) p=0.001,
while the adjusted HR showed no significant effect (HR 1.25
[0.87–1.78] p=0.23).
Figure 2. Increased FABP4 expression in atherosclerotic carotid
plaques from symptomatic patients. mRNA levels of FABP4 in
atherosclerotic carotid plaques were measured in 12 patients with
asymptomatic carotid plaques, in 25 patients with symptoms within the
last months (,1 month) and in 17 patients with symptoms 1–6 months
prior to collection. mRNA levels were quantified by real-time RT-PCR.
The expression of b-actin was used as endogenous control. Data are
mean 6 SEM. *p,0.05 compared to asymptomatic patients.
doi:10.1371/journal.pone.0028785.g002
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of FABP4 was weakened (HR=2.04 95% CI=1.0923.84;
P=0.027, Figure 5D) for all-cause mortality and not significant
for CV mortality (HR=1.49 95% CI=0.6223.59; P=0.38).
There were very few deaths within the first 30 days (n=7),
indicating that FABP4 levels at baseline may reflect the severity of
the underlying atherosclerotic process rather than the severity of
the index stroke (i.e., SSS). We therefore next looked at the
combinations of tertiles of SSS score and FABP4 (Figure 5E) and
found that the combination of high FABP4 and high stroke
severity (ie. tertile 3) gave a high HR in relation to all cause (HR
3.20 95%CI=1.6126.34; P=0.001) and CV (HR 4.53 95%CI=
1.96210.47; P,0.001) mortality in univariate analysis. For all
cause mortality, multivariate analysis indicated that the interaction
term between the top tertiles of stroke severity and FABP4 was
preferred over these factors alone with a similar HR as in
univariate analysis (HR 3.27 95%CI=1.4627.34; P=0.004).
This was not the case in multivariate analysis of CV mortality
where SSS score was preferred. Finally, we did not find that
addition of FABP4 to the fully adjusted multivariate model had an
effect on the prognostic discrimination for all-cause mortality (c-
statistic without FABP4 0.741, with FABP4 0.747, p=0.65) or CV
mortality (c-statistic without FABP4 0.812, with FABP4 0.820,
p=0.37).
Figure 3. FABP4 is co-localized to macrophages within carotid atherosclerotic plaques. Panel A shows immunostaining of FABP4 in
symptomatic carotid atherosclerotic plaques (n=2) primarily located to macrophage-rich areas. Representative images obtained with 10x and 40x
objective. Panel B shows double immunofluorescent staining of FABP4 (green fluorescence), CD68 (macrophages, red fluorescence) and nucleus
(DAPI, blue fluorescence) from symptomatic carotid atherosclerotic plaques (n=2). The lower panel is a merge of the three pictures above. Panel C
shows the correlations of mRNA levels in atherosclerotic plaques between FABP4, ADFP and CD68, respectively.
doi:10.1371/journal.pone.0028785.g003
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In the present study we have shown elevated FABP4 levels in
patients with carotid atherosclerosis, both systemically and within
the atherosclerotic lesion, with particularly high mRNA levels in
carotid plaques from those with the most recent symptoms.
Immunostaining of carotid plaques located FABP4 to macrophag-
es, and plaque analyses showing a strong correlation between
FABP4 and CD68 and ADRP, suggest that FABP4 could be a
marker of lipid accumulation and macrophage infiltration within
the lesion. Our in vitro findings also indicate a link between lipids
and FABP4 expression within macrophages. Moreover, during
acute ischemic stroke, high plasma levels of FABP4 were
associated with total mortality and CV mortality during follow-
up. The current study suggests that FABP4 may be related to
carotid atherosclerosis, potentially reflecting plaque instability and
poor outcome. However, future studies in larger stroke popula-
tions with differing etiology, reflecting the general stroke
population, are needed to evaluate if FABP4 could be a biomarker
for clinical risk stratification in patients with acute ischemic stroke.
Two recent studies have reported an association between the
expression of FABP4 within carotid lesion and plaque instability,
[9,10] Peeters et al. [10] reported that high expression of FABP4
within the atherosclerotic lesion was predictive of the occurrence
of adverse CV events. In the present study we extend these
findings by showing that high plasma levels of FABP4 during acute
ischemic stroke are associated with total and CV mortality during
longitudinal follow-up. The ability of biomarkers to predict
adverse outcome in atherosclerotic disorders may reflect their
capacity to mirror several upstream pathways that are of
Figure 4. Oxidized LDL and platelets enhances FABP4 in macrophages. Panel A shows mRNA expression of FABP4 in THP-1 cells during
PMA differentiation (left) and in THP-1 macrophages stimulated with oxidized LDL (20 mg/ml), TNFa (5 ng/ml) or both for 18 hours. mRNA levels were
quantified with the use of real-time RT-PCR. The expression of b-actin was used as endogenous control. Panel B shows the release of FABP4 protein
into the cell medium, as determined by enzyme immunoassay, in THP-1 monocytes that had been pre-incubated with rhTNFa (5 ng/ml) for 96 hours
before being incubated with LPS (5 ng/ml), a TLR2 agonist (Pam3Cys, 1 mg/ml), isoproterenol (20 mM), rh-IL-1b (1 ng/ml) and platelet releasate from
un-stimulated (UPRL) and thrombin-activated platelets (SPRL) for additional 20 hours. Data are mean 6 SEM relative to values in un-stimulated cells
(control). *p,0.05 and **p,0.001 versus control (or 0 hours [h] in panel A, left).
doi:10.1371/journal.pone.0028785.g004
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risk marker in CV, and it may be claimed that FABP4 is just
another acute phase protein. However, although several biomark-
ers are inferior to CRP in patients with ischemic stroke, studies on
other markers may be of importance to characterize the network
of mediators that are involved in the development of this complex
disorder.
The ability of oxLDL to enhance the expression of FABP4 in
macrophages, as also shown in the present study, underscores a
link between FABP4 levels and abnormal lipid metabolism during
atherogenesis. Our data from plaque analyses further suggest that
FABP4 could be a marker of lipid accumulation and macrophage
infiltration within the lesion. The lack of correlation between
plasma levels of FABP4 and lipid parameters may apparently seem
Figure 5. High plasma levels of FABP4 are associated with long-term mortality in patients with acute stroke. Panel A shows ROC curve
analysis for the predictive value of FABP4 for all-cause and CV mortality. AUC and 95% CI are given. Panel B shows Kaplan-Meier curves with the
cumulative incidence of all-cause and CV mortality during the entire study [median follow-up 4.4 years (interquartile range: 3.7 to 4.9 years)],
according to tertiles of FABP4 at admission. Panel C shows the restricted cubic spline analysis of FABP4 in relation to all-cause mortality. Panel D
shows multivariate analyses of FABP4 as an independent predictor of mortality in patients with acute stroke. *3
rd tertile vs. lower 2. Panel E shows the
increase in hazard ratios (HR) for the prediction of all-cause and CV mortality when combing tertiles of FABP4 and SSS score (inverse for SSS, ie.
increasing severity with higher tertiles). Tertile 1 was set as reference and the combination of T3 for both parameters is shown.
doi:10.1371/journal.pone.0028785.g005
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difficult to interpret, in particular as lipid status is modified by
statins that was used by the majority of the patients. FABP4 has
also been related to inflammatory responses within macrophages,
and was recently also shown to regulate endoplasmatic reticulum
homeostasis in these cells during atherosclerosis. [17] Somewhat
surprisingly, we found no correlation between plasma levels of
FABP4 and CRP, potentially reflecting that these markers may
mirror different parts of the inflammatory arm of atherogenesis.
Thus, it is tempting to hypothesize that the association of FABP4
with adverse outcome in stroke patients may reflect its ability to
mirror upstreams pathways (e.g., lipid interaction with macro-
phages) that are only partly reflected by other biomarkers.
In the cross-sectional part of the study we found that while
plasma levels of FABP4 did not differ between asymptomatic and
symptomatic patients, plaque expression of FABP4 were higher in
those with symptomatic lesions. It is possible that while plasma
levels of FABP4 reflect the chronic atherosclerotic process, the
expression of FABP4 within the atherosclerotic lesion will more
directly be related to plaque instability and plaque inflammation at
least in part reflecting the number of infiltrating macrophages
within the lesion. This notion was also supported by the current
data showing a strong correlation between FABP4 and CD68
within the atherosclerotic lesion. In the longitudinal study we
found that the association between baseline levels of FABP4 and
total mortality during follow-up mainly reflect an association
between FABP4 and CV mortality. There were very few deaths
within the first 30 days, further suggesting that FABP4 levels at
baseline may reflect the severity of the underlying atherosclerotic
process rather than the severity of the index stroke.
Our in vitro studies in THP-1 cells may suggest a link between
platelet activation and enhanced expression of FABP4 within
macrophages, at least partly dependent of pre-activation with
TNFa. In contrast, we found no correlation between plasma levels
of FABP4 and platelet counts or b-TG as a marker of platelet
activation in vivo. Although these latter findings could have been
influenced by the use of aspirin in the majority of patients, and
although we can not exclude an interaction between platelets and
monocytes/macrophages within the atherosclerotic lesion, further
studies are needed to make any conclusion on the role platelet-
monocyte/macrophage interaction in the regulation of FABP4
level.
In addition to be a marker of accelerated atherosclerosis,
FABP4 may also be an important mediator in this process.
Deletion of FABPs, including FABP4, in adipocytes has been
reported to result in reduced expression of inflammatory cytokines
in macrophages. [18] Moreover, an orally active small-molecule
inhibitor of aP2 (the mice homologue to FABP4) has been found to
be an effective therapeutic agent against severe atherosclerosis and
type 2 diabetes in mouse models. [19] Genetically and chemical
modification of aP2 have also been shown to protect against the
deleterious effects of hyperlipidemia in macrophages. [17] Thus,
the importance of FABP4 as a mediator seems to involve
adipocytes, macrophages and their interaction. The combined
properties of being a mediator as well as a marker of enhanced
atherogenesis may further support its potential role as a biomarker
in stroke and related disorders. However, although the association
between FABP4 and mortality in multivariate cox regression as
well as other data in this manuscript suggest that FABP4 may be
linked to enhanced atherogenesis, we did not find that addition of
FABP4 to the fully adjusted multivariate model had an effect on
the prognostic discrimination for all-cause mortality as assessed by
c-statistics. Our interpretation is that FABP4, at least at present, is
not a ‘‘stand alone’’ biomarker which can be used clinically to
identify patients at risk, but our findings suggest that studying
circulating FABP4 in larger stroke populations could be of interest
The current study has some limitations. The exclusion criteria
represent both strength and a weakness. By excluding patients with
atrial fibrillation, overt ischemic heart disease or patients with
onset of stroke symptoms .7 days before admission, all states
characterized by an increased inflammatory component, it seems
likely that the FABP4 levels do not merely reflect inflammatory
responses in concurrent disorders. However, the exclusion of many
patients also represents a weakness since the relevance of our
findings to the general stroke population remains unknown, and
unfortunately, we lack data on the clinical characteristics of the
screened patients that were not included. Moreover, the number
of patients that were included in the cross-sectional study was
rather low, and data from this part of the study should be
interpreted with caution. Furthermore, the lack of data on HbA1c
as an important risk factor, and a more reliable marker on glucose
metabolism than fasting glucose, in patients with acute stroke is a
limitation of this part of the study. Also, correlation analyses
should be interpreted with caution, and further mechanistic studies
as well as studies in larger stroke populations are needed to
elucidate the role of FABP4 in atherosclerotic disorders.
Nonetheless, our findings may suggest a link between FABP4
and atherogenesis and plaque instability in patients with carotid
atherosclerosis and acute ischemic stroke.
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